Novel repurposing of sulfasalazine for the treatment of adrenocortical carcinomas, probably through the SLC7A11/xCT-hsa-miR-92a-3p-OIP5-AS1 network pathway
SAS downregulates tSLC7A11 in ACCs, targets the Akt/ERK pathway and lipid metabolism, and induces cell death in vitro, warranting additional translational studies to define its therapeutic potential in ACC.
Authors
- Jonathan V. Sweedler (ORCID: https://orcid.org/0000-0003-3107-9922)
- Kelli McNamara
- Seth W. Croslow
- Yanqi Tan (ORCID: https://orcid.org/0009-0000-5302-547X)
- Katja Kiseljak‐Vassiliades (ORCID: https://orcid.org/0000-0003-3341-582X)
- Mark S. Cohen (ORCID: https://orcid.org/0000-0002-2517-0757)
- Chitra Subramanian (ORCID: https://orcid.org/0000-0003-1871-2834)
- Margaret E. Wierman (ORCID: https://orcid.org/0000-0002-7634-1093)
- Daniel L. Hess (ORCID: https://orcid.org/0000-0002-2476-3921)
Institutions
- University of Illinois Urbana-Champaign (US)
- Illinois College (US)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Surgery
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1016/j.surg.2024.07.075
- Citations
- 8
- Primary Topic
- Adrenal and Paraganglionic Tumors
- Type
- article
- Field-Weighted Citation Impact
- 4.58
Funders
- National Institutes of Health
- University of Illinois at Urbana-Champaign